2018
DOI: 10.1007/s00393-018-0545-z
|View full text |Cite
|
Sign up to set email alerts
|

Refractory chylous pleural effusion with systemic lupus erythematosus

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

1
2
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 11 publications
1
2
0
Order By: Relevance
“…Two studies reported the occurrence of chylothorax at 120 and 20 to 120 months, respectively, after the diagnosis. 9 , 10 Our patient shared this characteristic as he was diagnosed 86 months prior. However, more extensive studies are required to understand the risk conferred by these factors through multivariate regression analyses, as selection bias cannot be excluded with this sample size.…”
Section: Discussionsupporting
confidence: 59%
See 1 more Smart Citation
“…Two studies reported the occurrence of chylothorax at 120 and 20 to 120 months, respectively, after the diagnosis. 9 , 10 Our patient shared this characteristic as he was diagnosed 86 months prior. However, more extensive studies are required to understand the risk conferred by these factors through multivariate regression analyses, as selection bias cannot be excluded with this sample size.…”
Section: Discussionsupporting
confidence: 59%
“… 6 The observed refractoriness could be linked to lymphoscintigraphy findings of residual adhesions or thoracic duct obstructions that persist after SLE systemic inflammation’s resolution. 10 Surgical procedures may be needed in these cases and have shown better responses than medical therapy alone. In our case, medical treatment was ineffective in the short-term follow-up but achieved remission in the long term.…”
Section: Discussionmentioning
confidence: 99%
“…8,10 But refractory cases to the previous treatment were documented, and, in such cases, intravenous immunoglobulin was considered, and some cases responded well to talc pleurodesis and surgical pleurectomy. 5,18 In this case, the patient responded to rituximab with clinical and radiological improvement. Few similar cases were documented, as in a case reported by Ocampo V et al, 19 in which a 22-year-old male with SLE developed recurrent pericardial and massive unilateral pleural effusion and responded well to tocilizumab.…”
Section: Discussionmentioning
confidence: 71%